Observational study in healthy subjects and patients with Chronic obstructive pulmonary disease (COPD) to assess the relationship between clinical, imaging and biomarker measurements, and progression of emphysema over three years

  • Research type

    Research Study

  • Full title

    Observational study in healthy subjects and patients with Chronic obstructive pulmonary disease (COPD) to assess the relationship between clinical, imaging and biomarker measurements, and progression of emphysema over three years.

  • IRAS ID

    190627

  • Contact name

    Dave Singh

  • Contact email

    dsingh@meu.org.uk

  • Sponsor organisation

    Boehringer Ingelheim

  • Duration of Study in the UK

    2 years, 9 months, 10 days

  • Research summary

    Summary of Research

    This study will assess the relationship between clinical, imaging and biomarker measurements, and progression of emphysema over two years (104 weeks). This study will be conducted on healthy subjects and patients with COPD, to identify bio-markers (soluble, functional imaging and physiological) that may be useful in differentiating a patient population with ongoing emphysematous destruction of lung parenchyma, which may enable development of drugs aiming at the reduction of COPD. There will be no direct benefit for the participating subjects except the benefit which derives from the periodic monitoring of their health or disease status by the investigator and site staff. All subjects are allowed to continue their usual care. This study will include 125 healthy subjects (ex-smokers without airflow limitation), 125 COPD GOLD 1, 125 COPD GOLD 2, 125 COPD GOLD 3, and up to 40 (with a minimum of 20) patients with COPD and A1AT deficiency (ZZ genotype). Soluble and imaging biomarkers will be investigated addressing different aspects of disease pathways postulated to be relevant for COPD progression.

    Clinical assessments will consist of Spirometry, Body plethysmography, Pulse oximetry, DL,CO, Symptom questionnaires: mMRC, CAT, SGRQ, BODE index, 6 MWT

    Biofluid collection will consist of Sputum, Blood, Urine

    Imaging assessments will consist of chest computed tomography (CT), Magnet Resonance Imaging (MRI in a subset population)

    Summary of Results

    As this was a biomarker only study, no Lay Summary will be produced

  • REC name

    North West - Greater Manchester East Research Ethics Committee

  • REC reference

    16/NW/0104

  • Date of REC Opinion

    8 Apr 2016

  • REC opinion

    Further Information Favourable Opinion